In collaboration with leading cardiologists and cardiovascular researchers, SemBioSys has confirmed the activity of plant-derived Apo AI(Milano) in seven preclinical models. The Company has demonstrated the anti-atherosclerotic effects of Apo AI(Milano) based on cholesterol mobilization from the arterial wall, lipid content of atherosclerotic plaques, and the reduction of overall volume of atherosclerotic plaque after multiple injections. This year, the Company harvested more than 20 tonnes of safflower containing Apo AI(Milano) from outdoor production operations in Chile and the United States which provided surplus material for the manufacturing scale up at its pilot facility. SemBioSys has also completed a pre-IND (Investigational New Drug) meeting during which the U.S. Food and Drug Administration confirmed the development plan presented by SemBioSys to file an IND application and addressed the proposed design of clinical trials for Apo AI(Milano). SemBioSys continues to conduct discussions with potential partners on its proprietary, plant-derived Apo AI(Milano) product.

SOURCE SemBioSys Genetics Inc.